Short-time-intestinal-bowel model for the efficacy studies with novel anti-inflammatory drugs

Species

Rat

Fields of application

Treatment of inflammatory bowel disease (IBD) and the exploration of novel therapies represent an important research field. We established a short-time-intestinal-bowel model that could serve as an experimental test system that enables the investigation of early mucosal inflammation of IBD pathogenesis and a rapid screening of novel therapeutic options. Local mucosal inflammation is induced by an in situ perfusion of a defined segment of the small intestine with the sulfhydryl blocker iodoacetamide leading to an intestinal inflammation within two hours limited to the perfused segment only.

• Basic IBD research
• Testing novel therapeutic agents
• Drug testing

Endpoints/Outcome parameter

• Acute Intestinal Inflammation
• Treatment response

Readout parameter

• Staining and Histology: conventional staining and tissue pathohistology/conventional microscopy (e.g. tissue cell infiltration), immunohistochemistry/fluorescence microscopy, confocal microscopy (e.g. for detection of targets e.g. receptor expression)
• Intestinal tissue analysis (RNA isolation/ gene expression, cytokine profiles, protein expression…)
• Blood and organs recovering for further analysis possible

Quality management and validation

• Blinded data collection and evaluation
• Reference compounds dexamethasone and Mutaflor

References

• Breitrück A, Sparmann G, Mitzner S, Kerkhoff C. Establishment of a novel extracorporeal bowel model to study luminal approaches to treat inflammatory bowel disease. Dis Model Mech. 2013 Nov;6(6):1487-93. doi: 10.1242/dmm.011734. Epub 2013 Aug 14.978-3-8381-0572-7